A Study of PF-08653945 and PF-08653944 for Overweight or Obesity (SOLIS-1)
This study, called SOLIS-1, is looking into the safety and effects of two investigational drugs, PF-08653945 and PF-08653944, for adults who are overweight or have obesity. You might receive one of these drugs alone, both together, or a placebo (an inactive substance). The main goal is to see how much your body weight changes from the start of the study to Week 48. You could be eligible if you are 18 or older and have obesity (BMI 30.0-50.0 kg/m2) or are overweight (BMI 27.0-<30.0 kg/m2) with at least one weight-related health issue like high blood pressure or sleep apnea. The study plans to enroll 872 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study comparing investigational drugs PF-08653945 and PF-08653944 to a placebo. It aims to enroll 872 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures body weight change from the start of the study to Week 48.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
At a glance
Conditions
Where it's being run
65 sites across 23 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Percent change from baseline in body weightBaseline (Week 0) to Week 48